TGTX
TG Therapeutics, Inc.
TGTX's fundamentals are strong, but it looks expensive: trading at 98x earnings, more than twice its usual 39x. Its downside scenario is about six times its upside.
TGTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
TGTX's revenue, profitability, cash flow and balance sheet are all currently healthy.
TGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $7.91 | -88% |
| Forward | 26x | $64.56 | — |
| Fair | 39x | $25.80 | -60% |
| Current | 98x | $64.56 | — |
| Expensive | 148x | $97.38 | +51% |
Historical ranges are pointers, not guarantees.
TGTX's PE is in its expensive range at 98x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its fair range.
TGTX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for TGTX, with profitability improving. However, they disagree widely on these estimates.
TGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.52 | +282% |
| Q3 2026 | $0.66 | -76% |
| Q2 2026 | $2.74 | +621% |
| Q1 2026 | $2.86 | +1044% |
| Q4 2025 | $2.77 | +1747% |
| Q3 2025 | $2.79 | +$2.89 |
| Q2 2025 | $0.38 | -38% |
| Q1 2025 | $0.25 | +8.7% |
| Q4 2024 | $0.15 | +650% |
TGTX earned $0.66 per share over the past year, down 76% from the year before.
TGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $259.9M | +61% |
| Q2 2026 | $240.3M | +70% |
| Q1 2026 | $204.9M | +70% |
| Q4 2025 | $192.6M | +78% |
| Q3 2025 | $161.7M | +93% |
| Q2 2025 | $141.1M | +92% |
| Q1 2025 | $120.9M | +90% |
| Q4 2024 | $108.2M | +146% |
TGTX's revenue has grown year over year for eight quarters in a row: $260M last quarter, up 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +15 points |
| Q2 2026 | 9% | -16 points |
| Q1 2026 | 17% | +9.9 points |
| Q4 2025 | 26% | -1.5 points |
| Q3 2025 | 18% | +3.3 points |
| Q2 2025 | 25% | +13 points |
| Q1 2025 | 7.1% | +22 points |
| Q4 2024 | 28% | +56 points |
TGTX's operating margin was 33% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
TGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44.9M | +$68.2M |
| Q2 2026 | $39M | +427% |
| Q1 2026 | -$17.9M | +$10.8M |
| Q4 2025 | $19.6M | +$45.3M |
| Q2 2025 | $7.4M | +34% |
| Q1 2025 | -$28.7M | -$20.5M |
| Q4 2024 | -$25.7M | -$12.5M |
| Q4 2023 | -$13.2M | +$10.7M |
TGTX's free cash flow has turned positive after five years mostly in the red: $86M over the past year.
TGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.4M shares |
| 1 year | -3.2% | -5.1M shares |
| 3 years | 0% | +53.3K shares |
| 5 years | +18% | +23.6M shares |
| Available history | +76% | +67.6M shares |
TGTX has 156M diluted shares, down 3.2% from a year ago, with $200M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100M |
| Q2 2026 | — |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $78.2M |
| Q2 2025 | $6.9M |
| Q1 2025 | $6.1M |
| Q4 2024 | $6.6M |
TGTX spent $200M buying back its own shares over the past year, up 104% from the year before.
TGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.5x | Healthy |
TGTX's net debt is about 1.6 years of its operating earnings (EBITDA), about the same as a year ago.
TGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 86.3 | Overbought |
TGTX's weekly RSI is 69 (neutral) and its Stochastic is 86 (overbought).
TGTX PE vs Healthcare Sector
| Metric | TGTX | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 75 | 29 | 46 pts above |
TGTX is trading at 98x earnings, a 278% premium to the Healthcare sector's median of 26x.
TGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.6 | 12% above |
| 20 week MA | $55.4 | 17% above |
| 50 week MA | $43.0 | 50% above |
| 100 week MA | $38.7 | 67% above |
| 200 week MA | $28.6 | 126% above |
TGTX is in an uptrend: it's above all five of its weekly moving averages, and 126% above its 200-week average.
TGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $53.3 | +390% |
| 2021 | $53.3 | $19.4 | -64% |
| 2022 | $19.4 | $8.12 | -58% |
| 2023 | $8.12 | $17.1 | +110% |
| 2024 | $17.1 | $32.5 | +90% |
| 2025 | $32.5 | $30.8 | -5.4% |
| 2026 YTD | $30.8 | $64.6 | +110% |
TGTX's yearly returns have swung widely, from +390% in 2020 to −64% in 2021. It's up 110% so far in 2026.